ArticleBritish journal of cancer2023

The heterogeneity of tumour immune microenvironment revealing the CRABP2/CD69 signature discriminates distinct clinical outcomes in breast cancer.

Jie Mei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.